- Home
- LAUR vs PTGX Comparison
LAUR vs PTGX Comparison
Compare LAUR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAUR
- PTGX
- Stock Information
- Founded
- LAUR 1989
- PTGX 2006
- Country
- LAUR United States
- PTGX United States
- Employees
- LAUR N/A
- PTGX N/A
- Industry
- LAUR Other Consumer Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- LAUR Real Estate
- PTGX Health Care
- Exchange
- LAUR Nasdaq
- PTGX Nasdaq
- Market Cap
- LAUR 3.5B
- PTGX 3.3B
- IPO Year
- LAUR 2017
- PTGX 2016
- Fundamental
- Price
- LAUR $25.80
- PTGX $55.78
- Analyst Decision
- LAUR Buy
- PTGX Strong Buy
- Analyst Count
- LAUR 1
- PTGX 8
- Target Price
- LAUR $24.00
- PTGX $70.13
- AVG Volume (30 Days)
- LAUR 1.1M
- PTGX 633.4K
- Earning Date
- LAUR 07-31-2025
- PTGX 08-06-2025
- Dividend Yield
- LAUR N/A
- PTGX N/A
- EPS Growth
- LAUR 35.40
- PTGX N/A
- EPS
- LAUR 1.68
- PTGX 0.80
- Revenue
- LAUR $1,552,343,000.00
- PTGX $209,180,000.00
- Revenue This Year
- LAUR $3.41
- PTGX N/A
- Revenue Next Year
- LAUR $7.90
- PTGX $53.09
- P/E Ratio
- LAUR $15.44
- PTGX $68.40
- Revenue Growth
- LAUR 0.44
- PTGX N/A
- 52 Week Low
- LAUR $14.45
- PTGX $33.31
- 52 Week High
- LAUR $26.72
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- LAUR 67.14
- PTGX 53.03
- Support Level
- LAUR $25.60
- PTGX $50.49
- Resistance Level
- LAUR $26.72
- PTGX $56.85
- Average True Range (ATR)
- LAUR 0.69
- PTGX 2.05
- MACD
- LAUR 0.24
- PTGX 0.08
- Stochastic Oscillator
- LAUR 80.92
- PTGX 64.04
About LAUR Laureate Education Inc.
Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions. Its geographical segments include Peru and Mexico.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.